Patient Reported Outcomes and Quality of Life Considerations

This segment examines patient-reported outcomes and quality of life in the LITESPARK-011 trial. The findings indicate that overall quality of life was similar between the combination therapy and cabozantinib, despite differences in toxicity profiles. The discussion highlights that while the combination improves disease control, it does not clearly enhance patient-reported outcomes compared with single-agent therapy. The speakers emphasize the importance of incorporating patient perspectives into treatment decisions, particularly when balancing efficacy and tolerability. This segment underscores the role of quality-of-life data in guiding clinical practice and supports the need for shared decision-making between clinicians and patients.